comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 16:25:08 - browse：7835

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Menendez indictment could see pharma lose a key ally

Wikipedia

WSS

Shingles, which affected Dianne Feinstein, is on the rise

STAT Readout Newsletter: Today's biggest biotech updates

Menendez indictment could see pharma lose a key ally

FDA advisers vote against ALS treatment from BrainStorm

Senate committee scrutinizes Medicare Advantage brokers

The explosion of genetic testing requires a new approach

hotspot

comprehensive

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA advisers vote against ALS treatment from BrainStorm

Drug repurposing or repositioning? The language matters

How one patient went off dialysis — and others can too

Novavax promises a turnaround & Lilly roils the obesity market

Mindstrong's demise and the future of mental health care

After affirmative action ruling, medical educators look to 'holistic review'

Solve the antibiotic resistance crisis with preventive drugs

BioMarin wins approval for gene therapy to treat hemophilia A

Researchers use wearables data and AI to predict preterm birth risk

explore

STAT Summit: Biotech founders on deal

Eli Lilly expects to double planned employment in Boston center

CEOs share strategies for surviving biotech slump

Intercept Pharmaceuticals sells itself for less than $1 billion

FDA warns J&J's Abiomed: We will regulate your software

Paxlovid should be available without a positive Covid test

focus

Wikipedia

hotspot

entertainment